Table 1.

National Comprehensive Cancer Network (NCCN) Guidelines (7).

	Preferred regimens	Other regimens
Primary therapy for transplant candidates (assess for response after 2 cycles)	Bortezomib/dexamethasone (category 1) Bortezomib/cyclophosphamide/dexamethasone Bortezomib/doxorubicin/dexamethasone (category 1) Bortezomib/lenalidomide/dexamethasone Bortezomib/thalidomide/dexamethasone (category 1) Lenalidomide/dexamethasone (category 1)	Carfilzomib/lenalidomide/dexamethasone Dexamethasone (category 2B) Ixazomib/lenalidomide/dexamethasone Liposomal doxorubicin/vincristine/dexamethasone (DVD) (category 2B) Thalidomide/dexamethasone (category 2B)
Primary therapy for non-transplant candidates (assess for response after 2 cycles)	Bortezomib/dexamethasone Bortezomib/cyclophosphamide/dexamethasone Bortezomib/lenalidomide/dexamethasone (category 1) Lenalidomide/low-dose dexamethasone (category 1) Melphalan/prednisone/bortezomib (MPB) (category 1) Melphalan/prednisone/lenalidomide (MPL) (category 1) Melphalan/prednisone/thalidomide (MPT) (category 1)	Dexamethasone (category 2B) Ixazomib/lenalidomide/dexamethasone Liposomal doxorubicin/vincristine/dexamethasone (DVD) (category 2B) Melphalan/prednisone (MP) Thalidomide/dexamethasone (category 2B) Vincristine/doxorubicin/dexamethasone (VAD) (category 2B)
Maintenance therapy	Bortezomib Lenalidomide (category 1) Thalidomide (category 1)	Bortezomib + prednisone (category 2B) Bortezomib + thalidomide (category 2B) Interferon (category 2B) Steroids (category 2B) Thalidomide + prednisone (category 2B)